Amgen Inc.
News and overview for Amgen Inc.
Is Amgen retreat a case of investor overreaction? - MarketWatch
MarketWatch | 19 days 8 hours 36 minutes ago
Investors have had high hopes for Prolia, with many expecting the product to jump-start Amgen's sputtering top line and potentially help transform the biotech giant back into the growth story of yore.
Amgen reports higher third-quarter profit - MarketWatch
MarketWatch | 34 days 5 hours 12 minutes ago
The Thousand Oaks, Calif.-based biotech giant posted net income of $1.39 billion, or $1.36 a share, compared with $1.12 billion, or $1.05 a share, for the same period in 2008.
FDA requests additional studies for Amgen drug - MarketWatch
MarketWatch | 34 days 5 hours 12 minutes ago
AMGN
14 states sue Amgen over alleged kickbacks - MarketWatch
MarketWatch | 25 days 6 hours 48 minutes ago
The companies also allegedly offered kickbacks such as paid vacations to prescribers in order to boost sales of the product, Cuomo's office claimed.
Amgen drug faces FDA approval delay - MarketWatch
MarketWatch | 36 days 13 hours 19 minutes ago
AMGN
Drug stocks split; Amgen falls on FDA delay - MarketWatch
MarketWatch | 36 days 11 hours 59 minutes ago
Shares of Amgen /quotes/comstock/15*!amgn/quotes/nls/amgn (AMGN 60.01, -1.31, -2.14%) were down 2% to $60.10.
NY, other states sue Amgen over alleged kickbacks - MarketWatch
MarketWatch | 25 days 7 hours 52 minutes ago
AMGN
Ebay, Amgen results on tap for evening session - MarketWatch
MarketWatch | 34 days 6 hours 50 minutes ago
Analysts anticipate the online marketplace will report earnings of 37 cents a share on a non-GAAP basis, down from 46 cents a share last year. Revenue is expected to rise slightly to $2.14 billion from $2.12 billion the same period last year. See full story.
ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Company s TAP Technology [Press Release]
Business Wire | 5 days 5 hours 19 minutes ago
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, today announced that Amgen Inc. has licensed the exclusive right to use the Company’s maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target. This is the second such license to be taken by Amgen – the company licensed the exclusive right to use ImmunoGen’s TAP technology for another undisclosed cancer target in September 2009.
Amgen Provides Update on Status of Prolia(TM) (Denosumab) Biologics License Application (BLA) Submitted to the U.S. Food and Drug Administration (FDA) [Press Release]
PRNewswire | 36 days 9 hours 20 minutes ago
Amgen Provides Update on Status of Prolia(TM...Oct. 19 /PRNewswire-FirstCall/ -- Amgen Inc. today announced that the U.S. Food...Photo Desk, photodesk@prnewswire.com Amgen Inc. CONTACT: Media, David Polk, +1...
Amgen receives Complete Response Letter for the Biologic License Applications for Prolia from FDA
News-Medical.Net | 36 days 11 hours 56 minutes ago
Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Applications (BLA) for Prolia(TM) (denosumab) in the treatment and prevention of postmenopausal osteoporosis.
Thursday's biggest gaining and declining stocks - MarketWatch
MarketWatch | 33 days 13 hours 58 minutes ago
What's fueling eBay's revenue growth. 5:36 p.m. Oct. 21, 2009 | Comments: 4
Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting [Press Release]
PRNewswire | 103 days 3 hours 19 minutes ago
...Calif., Aug. 13 /PRNewswire-FirstCall/ -- Amgen Inc. issued the following statement on the outcome...orgPRN Photo Desk, photodesk@prnewswire.com Amgen Inc. CONTACT: Amgen, Thousand Oaks, media, osteoporosis, Kerry Beth...
Amgen, Amerisource sued over drug kickback scheme
Forbes | 25 days 6 hours 54 minutes ago
* 14 states, Washington D.C., allege Aranesp kickbacks * States say Medicaid overcharged, weekend retreats givenArticle Controlsemail
Amgen to reduce price of Neulasta following Board's orders
News-Medical.Net | 27 days 13 hours 53 minutes ago
The Board issued a Notice of Hearing on March 16, 2009, pertaining to allegations of Board Staff that Neulasta had been, and was being, sold by Amgen Canada Inc. at prices exceeding those indicated by the Board's Excessive Price Guidelines. On October 13, 2009, the Hearing Panel received a Joint Submission by Amgen and Board Staff along with a Voluntary Compliance Undertaking ("VCU") which proposed to resolve the issues raised in the Neulasta proceedings.
Sign up for AANP SmartBrief
Company Overview
| Company: | Amgen Inc. |
|---|---|
| Industry: | Biopharmaceuticals & Biotherapeutics |
| Website: | http://www.amgen.com |
Amgen is among the biggest of the biotech big'uns, and it's determined to get even bigger. The company uses cellular biology and medicinal chemistry to target cancers, kidney ailments, inflammatory disorders, and metabolic diseases. Anti-anemia drugs Epogen and Aranesp account for more than one-third of its sales. Enbrel, another leading drug, treats rheumatoid arthritis and is one of the best-selling drugs in this multi-billion-dollar market. The company has a promising drug pipeline and marketing alliances with Japanese brewer and drugmaker Kirin, Johnson & Johnson, and other pharmaceutical companies. Amgen sells its products primarily through wholesale distributors in North America and Europe.
Key Numbers
| Sales in U.S. Dollars (mil.) | 15,003 (2008) |
|---|---|
| One-year % Growth in Sales | 1.6 (2008) |
| Net Income in U.S. Dollars (mil.) | 4,196 (2008) |
| One-year % Growth in Net Income | 32.5 (2008) |
| Number of Employees | 17,500 (2007) |
| One-year % Growth in Number of Employees | -12.9 (2007) |
| Fiscal Year-End | December |